108例铂类化疗药致药品不良反应报告分析  

Analysis of 108 Cases of Adverse Drug Reactions Induced by Platinum Chemotherapy Drugs

作　　者：钱嘉[1] 张雷[2] 吴楠[1] QIAN Jia;ZHANG Lei;WU Nan(Dept.of Pharmacy,Jiangsu Cancer Hospital/Jiangsu Institution of Cancer Research/The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Nanjing 210009,China;Dept.of Pharmacy,Traditional Chinese Medicine Hospital of Kunshan,Jiangsu kunshan 215300,China)

机构地区：[1]江苏省肿瘤医院/江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院药学部,江苏南京210009 [2]昆山市中医医院药剂科,江苏昆山215300

出　　处：《中国医院用药评价与分析》2021年第8期1014-1016,1020,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:了解铂类药物发生药品不良反应(adverse drug reaction,ADR)的特点,为临床安全用药提供参考。方法:收集2019年江苏省肿瘤医院(以下简称“我院”)上报的108例铂类药物致ADR报告,对患者的性别、年龄、原患疾病、药物使用情况、ADR发生时间、ADR累及器官和(或)系统及临床表现、是否联合用药以及转归等进行回顾性分析。结果:108例铂类药物致ADR报告中,病例数排序居前2位的药品为奥沙利铂(34例,占31.48%)、奈达铂(30例,占27.78%);ADR主要发生在高年龄段(>60~80岁)人群(63例,占58.33%);ADR多见于用药1 d后(75例,占69.44%);骨髓抑制是ADR的主要临床表现(78例,占72.22%);大多数发生ADR的患者存在联合用药(81例,占75.00%);严重的ADR共39例(占36.11%)。结论:应加强老年患者的用药监护,尤其是联合用药的患者。OBJECTIVE:To probe into the characteristics of adverse drug reactions(ADR)induced by platinum chemotherapy drugs,so as to provide reference for safe medication in clinic.METHODS:Totally 108 cases of ADR induced by platinum chemotherapy drugs in Jiangsu Cancer Hospital(hereinafter referred to as“our hospital”)in 2019 were collected,and patients gender,age,primary disease,drug use,ADR occurrence time,ADR involved organs and(or)system,clinical manifestations,drug combination and outcome were retrospectively analyzed.RESULTS:Of the 108 cases of ADR induced by platinum chemotherapy drugs,the top 2 drugs ranked by the number of cases were oxaliplatin(34 cases,31.48%)and nedaplatin(30 cases,27.78%).The patients aged>60-80 years accounted for the highest proportion(63 cases,58.33%).ADR was mostly seen after 1 d of administration(75 cases,69.44%).Bone marrow suppression was the main clinical manifestation of ADR(78 cases,72.22%).Most patients with ADR had drug combination(81 cases,75.00%).There were 39 cases(36.11%)of severe ADR.CONCLUSIONS:Medication monitoring in the elderly should be strengthened,especially in patients with drug combination.

关 键 词：铂类药物 药品不良反应 病例报告 

分 类 号：R979.1[医药卫生—药品]